Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Robert O Dillman. (2013) Melanoma vaccines: trials and tribulations. Vaccine: Development and Therapy 3, pages 57-78.
Read now
Read now
Robert O Dillman, Andrew N Cornforth & Gabriel Nistor. (2013) Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. Expert Opinion on Biological Therapy 13:5, pages 643-656.
Read now
Read now
Kristian Hallermalm. (2009) T-cell epitope analogues from carcinoembryonic antigen for vaccination against cancer: WO2009002418. Expert Opinion on Therapeutic Patents 19:11, pages 1635-1637.
Read now
Read now
Maurizio Chiriva-Internati, Everardo Cobos & W. Martin Kast. (2007) Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials. International Reviews of Immunology 26:3-4, pages 197-222.
Read now
Read now
Nikoletta L Kallinteris, Xueqing Lu, Catherine E Blackwell, Eric von Hofe, Robert E Humphreys & Minzhen Xu. (2006) Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opinion on Biological Therapy 6:12, pages 1311-1321.
Read now
Read now
Articles from other publishers (33)
Deqiu Huang, Tong Wu, Siyuan Lan, Chengkuan Liu, Zhouyi Guo & Wen Zhang. (2022) In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. Biomaterials 289, pages 121808.
Crossref
Crossref
Pejman HASHEMZADEH, Vajihe GHORBANZADEH & Hassan DARIUSHNEJAD. (2021) Predicted peptide-based MHC-I, MHC-II, CTL and B-cell epitopes of MUC-1 by immunoinformatics methods: a clue for novel multi-epitope vaccine development against breast cancer. Minerva Biotecnologica 32:4.
Crossref
Crossref
Neha Parayath, Smrithi Padmakumar, Shantikumar V. Nair, Deepthy Menon & Mansoor M. Amiji. (2019) Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. Regenerative Engineering and Translational Medicine 6:1, pages 29-49.
Crossref
Crossref
Yating Liu, Lintong Yao, Wenpeng Cao, Yajing Liu, Wenjie Zhai, Yahong Wu, Binglin Wang, Shanshan Gou, Yaping Qin, Yuanming Qi, Zhenzhen Chen & Yanfeng Gao. (2019) Dendritic Cell Targeting Peptide-Based Nanovaccines for Enhanced Cancer Immunotherapy. ACS Applied Bio Materials 2:3, pages 1241-1254.
Crossref
Crossref
J.M. Moskovitz & R.L. Ferris. (2018) Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. Journal of Dental Research 97:6, pages 622-626.
Crossref
Crossref
Qian Chen, Ligeng Xu, Chao Liang, Chao Wang, Rui Peng & Zhuang Liu. (2016) Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nature Communications 7:1.
Crossref
Crossref
Weihong Sun, Xiaofang Wei, Airong Niu, Xuezhen Ma, Jian Jian Li & Daiqing Gao. (2015) Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides. Cancer Letters 369:1, pages 112-123.
Crossref
Crossref
Negar Seyed, Tahereh Taheri, Charline Vauchy, Magalie Dosset, Yann Godet, Ali Eslamifar, Iraj Sharifi, Olivier Adotevi, Christophe Borg, Pierre Simon Rohrlich & Sima Rafati. (2014) Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived from Leishmania major Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps toward Polytope Vaccine. PLoS ONE 9:10, pages e108848.
Crossref
Crossref
Mohamed L. Salem. 2014. Cancer Vaccines. Cancer Vaccines
479
503
.
Hyun Ju Lee, Cheol Yi Hong, Chun-Ji Jin, Mi-Hyun Kim, Youn-Kyung Lee, Thanh-Nhan Nguyen-Pham, Hyunah Lee, Byoung Chul Park, Ik-Joo Chung, Hyeoung-Joon Kim & Je-Jung Lee. (2012) Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer. Cellular & Molecular Immunology 9:2, pages 175-183.
Crossref
Crossref
Andrey S. Dobroff, Elaine G. Rodrigues, Maria A. Juliano, Dayson M. Friaça, Ernesto S. Nakayasu, Igor C. Almeida, Renato A. Mortara, Jacqueline F. Jacysyn, Gustavo P. Amarante-Mendes, Walter Magliani, Stefania Conti, Luciano Polonelli & Luiz R. Travassos. (2010) Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. Translational Oncology 3:4, pages 204-217.
Crossref
Crossref
Nicolás Herbert, Axel Haferkamp, Hubertus F. Schmitz-Winnenthal & Margot Zöller. (2010) Concomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection. The Journal of Immunology 185:2, pages 902-916.
Crossref
Crossref
Yu-Qian Zhang, Ya-Chea Tsai, Archana Monie, Chien-Fu Hung & T.-C. Wu. (2010) Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine 28:32, pages 5212-5219.
Crossref
Crossref
Eftychia Lekka, Angelos D. Gritzapis, Sonia A. Perez, Nikolaos Tsavaris, Ioannis Missitzis, Avgi Mamalaki, Michael Papamichail & Constantin N. Baxevanis. (2009) Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunology, Immunotherapy 59:5, pages 715-727.
Crossref
Crossref
Lutz Gissmann & Karen Nieto. (2009) The Therapeutic Vaccine: Is it Feasible?. Archives of Medical Research 40:6, pages 493-498.
Crossref
Crossref
Barbara Seliger. 2009. Tumor‐Associated Antigens. Tumor‐Associated Antigens
219
229
.
Rikke Bæk Sørensen, Rikke Sick Andersen, Inge Marie Svane, Lotte Engell-Noerregaard, Sine R. Hadrup, Eva Balslev, Mads Hald Andersen & Per thor Straten. (2009) CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53. Clinical Cancer Research 15:5, pages 1543-1549.
Crossref
Crossref
Michael S. Leibowitz, Jayakar V. Nayak & Robert L. Ferris. (2008) Head and neck cancer immunotherapy: Clinical evaluation. Current Oncology Reports 10:2, pages 162-169.
Crossref
Crossref
Shanshan W. Howland & K. Dane Wittrup. (2008) Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency. The Journal of Immunology 180:3, pages 1576-1583.
Crossref
Crossref
Pedro Romero. (2008) Current State of Vaccine Therapies in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 9, pages S28-S36.
Crossref
Crossref
Nectaria N. Sotiriadou, Nikoletta L. Kallinteris, Angelos D. Gritzapis, Ioannis F. Voutsas, Michael Papamichail, Eric von Hofe, Robert E. Humphreys, Theodoros Pavlis, Sonia A. Perez & Constantin N. Baxevanis. (2006) Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunology, Immunotherapy 56:5, pages 601-613.
Crossref
Crossref
Yan Tang, Zhihua Lin, Bing Ni, Jing Wei, Junfeng Han, Huiming Wang & Yuzhang Wu. (2006) An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180–188) enhanced immunogenicity. Cancer Immunology, Immunotherapy 56:3, pages 319-329.
Crossref
Crossref
Jun-Feng Han, Ting-Ting Zhao, Hong-Li Liu, Zhi-Hua Lin, Hui-Ming Wang, Zhi-Hua Ruan, Li-Yun Zou & Yu-Zhang Wu. (2006) Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunology, Immunotherapy 55:12, pages 1575-1583.
Crossref
Crossref
S.B. Pai, R.B. Pai, R.M. Lalitha, S.V. Kumaraswamy, N. Lalitha, R.N. Johnston & M.K. Bhargava. (2006) Expression of oncofoetal marker carcinoembryonic antigen in oral cancers in South India—a pilot study. International Journal of Oral and Maxillofacial Surgery 35:8, pages 746-749.
Crossref
Crossref
Yeonseok Chung, Byung-Seok Kim, Yeon-Jeong Kim, Hyun-Jeong Ko, Sung-Youl Ko, Dong-Hyeon Kim & Chang-Yuil Kang. (2006)
CD1d-Restricted T Cells License B Cells to Generate Long-Lasting Cytotoxic Antitumor Immunity
In vivo
. Cancer Research 66:13, pages 6843-6850.
Crossref
Crossref
Christa Firbas, Bernd Jilma, Erich Tauber, Vera Buerger, Sandra Jelovcan, Karen Lingnau, Michael Buschle, Jürgen Frisch & Christoph S. Klade. (2006) Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24:20, pages 4343-4353.
Crossref
Crossref
Janet I. Malowany, Sarah McCormick, Michael Santosuosso, Xizhong Zhang, Naoko Aoki, Patricia Ngai, Jun Wang, Jaina Leitch, Jonathan Bramson, Yonghong Wan & Zhou Xing. (2006) Development of Cell-Based Tuberculosis Vaccines: Genetically Modified Dendritic Cell Vaccine Is a Much More Potent Activator of CD4 and CD8 T Cells Than Peptide- or Protein-Loaded Counterparts. Molecular Therapy 13:4, pages 766-775.
Crossref
Crossref
Dean Johnston, Sandra R. Reynolds & Jean-Claude Bystryn. (2005) Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice. Cancer Immunology, Immunotherapy 55:4, pages 412-419.
Crossref
Crossref
Dean Johnston & Jean-Claude Bystryn. (2006) Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24:11, pages 1958-1965.
Crossref
Crossref
Serenella M. Pupa, Elda Tagliabue, Sylvie Ménard & Andrea Anichini. (2005) HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. Journal of Cellular Physiology 205:1, pages 10-18.
Crossref
Crossref
Manuel Schmidt, Barbara Volz & Burghardt Wittig. 2005. Modern Biopharmaceuticals. Modern Biopharmaceuticals
183
211
.
Jorg Willers, Alberta Lucchese, Abraham Mittelman, Reinhard Dummer & Darja Kanduc. (2005) Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Experimental Dermatology 14:7, pages 543-550.
Crossref
Crossref
Mads Hald Andersen, Jürgen C. Becker & Per thor Straten. (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nature Reviews Drug Discovery 4:5, pages 399-409.
Crossref
Crossref